ArticleBMC cancer2021
Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 16 citations in OpenAlex.
- Rethinking mucinous colorectal adenocarcinoma classification: evidence from histopathology and RAS mutations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study.Journal of gastrointestinal oncology · 2026Article
- Histopathologic clues to mismatch repair deficiency in colon adenocarcinoma: the role of mucinous component and intratumoral/Crohn-like immune response.BMC gastroenterology · 2026Article
- L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability.Oncogene · 2026Article
- Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China.Journal of gastrointestinal oncology · 2026Article
- Acellular mucin in neoplastic and non-neoplastic conditions of the lower gastrointestinal tract.World journal of gastrointestinal surgery · 2025Review
- Prediction of mucinous adenocarcinoma in colorectal cancer with mucinous components detected in preoperative biopsy diagnosis.Abdominal radiology (New York) · 2025Article
- The Influence of Mucinous Histology on the Prognosis of Stage II and III Colorectal Cancers.Medicina (Kaunas, Lithuania) · 2025Article
- Comparative Outcomes of Neo-Adjuvant Chemo-Radiotherapy in Stage II and III Mucinous versus Non-Mucinous Rectal Adenocarcinoma: A Retrospective Study.Cancer management and research · 2025Article
- Transcriptomic Landscape of Colorectal Mucinous Adenocarcinoma has Similarity with Intestinal Goblet Cell Differentiation.Current genomics · 2025Article
- Unveiling the secrets of gastrointestinal mucous adenocarcinoma survival after surgery with artificial intelligence: A population-based study.World journal of gastrointestinal oncology · 2024Article
- Identification and validation of a novel six-gene signature based on mucinous adenocarcinoma-related gene molecular typing in colorectal cancer.Discover oncology · 2024Article
- Clinicopathological characteristics and outcomes of colorectal mucinous adenocarcinoma: a retrospective analysis from China.Frontiers in oncology · 2024Article
- Comparative analysis of the clinical aspects of colorectal cancer in young adult and older adult patients in Saudi Arabia.Frontiers in oncology · 2024Article
- Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery.Frontiers in oncology · 2024Article
- Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report.Frontiers in oncology · 2023Article
- Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate the clinical significance and prognostic value of mucinous component (MC) in colorectal adenocarcinoma (AC).
methodsPatients with colorectal AC and AC with MC (ACMC) (1-100%) underwent surgical resection between January 2007 and February 2018 were retrospectively reviewed. Propensity score matching (PSM) was performed according to a 1:1 ratio. Receiver-operating characteristic (ROC) curve was used to identify the optimal cut-off value of MC ratio for prognostic prediction. The clinicopathological features and 3-year overall survival (OS) of AC patients, mucinous adenocarcinoma (MAC) (MC > 50%) patients, and ACMC (1-50%) patients were compared before and after matching. Multivariable analysis was used for analyzing independent risk factors related to prognosis.
resultsA total of 532 patients were enrolled in this study. Patients with AC, MAC, and ACMC (1-50%) exhibited different clinicopathological features. However, their 3-year OS rates were similar (82.00% vs. 74.11% vs. 81.48%, P = 0.38). After matching, ROC curve determined 70% as the optimal cut-off value. And patients with ACMC > 70% had a much poorer 3-year OS compared with ACMC (1-70%) patients and AC patients (47.37% vs. 86.15% vs. 79.76%, P < 0.001). In addition, ACMC > 70% was revealed as a risk factor for poor survival in univariate analysis (HR = 1.643, 95%CI = 1.025-2.635, P = 0.039), though not an independent risk factor in multivariable analysis (HR = 1.550, 95%CI = 0.958-2.507, P = 0.074).
conclusionsMAC is usually diagnosed at an advanced stage. MAC has a similar survival with AC and ACMC (1-50%) patients before and after matching. Patients with ACMC > 70% exhibited a much poorer OS, and should be given more clinical attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.